



**Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **Ashley Rosko, M.D.**

Committee: **Oncologic Drugs Advisory Committee**

Meeting Date: **February 10, 2022**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On February 10<sup>th</sup>, the committee will discuss biologics license application (BLA) 761222, for sintilimab injection, submitted by Innovent Biologics (Suzhou) Co., Ltd. The proposed indication (use) for this product is in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with Stage IIIB, IIIC, or Stage IV non-squamous non-small cell lung cancer with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
None		
<b>II. Other Imputed Interests</b>		
Contracts/grants	Employer’s research funded by GlaxoSmithKline, a competing firm	\$0 – 50,000 per year to Ohio State University
Contracts/grants	Employer’s research funded by <span style="background-color: gray; color: black;">(b) (4)</span> , a competing firm	Dr. Rosko is not aware of the funding amount being provided to Ohio State University

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/S/  
Signature

\_\_\_\_\_  
Date